Logo image of TSBX

TURNSTONE BIOLOGICS CORP (TSBX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TSBX - US90042W1009 - Common Stock

0.355 USD
+0.01 (+1.43%)
Last: 8/8/2025, 8:09:47 PM
Fundamental Rating

2

TSBX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. The financial health of TSBX is average, but there are quite some concerns on its profitability. TSBX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TSBX has reported negative net income.
In the past year TSBX has reported a negative cash flow from operations.
TSBX Yearly Net Income VS EBIT VS OCF VS FCFTSBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -228.20%, TSBX is doing worse than 90.40% of the companies in the same industry.
TSBX's Return On Equity of -315.29% is on the low side compared to the rest of the industry. TSBX is outperformed by 72.64% of its industry peers.
Industry RankSector Rank
ROA -228.2%
ROE -315.29%
ROIC N/A
ROA(3y)-84.15%
ROA(5y)N/A
ROE(3y)-108.37%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TSBX Yearly ROA, ROE, ROICTSBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

TSBX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TSBX Yearly Profit, Operating, Gross MarginsTSBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

6

2. Health

2.1 Basic Checks

TSBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
TSBX has less shares outstanding than it did 1 year ago.
There is no outstanding debt for TSBX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TSBX Yearly Shares OutstandingTSBX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 50M 100M
TSBX Yearly Total Debt VS Total AssetsTSBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

TSBX has an Altman-Z score of -18.72. This is a bad value and indicates that TSBX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TSBX (-18.72) is worse than 83.33% of its industry peers.
There is no outstanding debt for TSBX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.72
ROIC/WACCN/A
WACC9.85%
TSBX Yearly LT Debt VS Equity VS FCFTSBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 3.70 indicates that TSBX has no problem at all paying its short term obligations.
TSBX has a Current ratio of 3.70. This is comparable to the rest of the industry: TSBX outperforms 44.02% of its industry peers.
A Quick Ratio of 3.70 indicates that TSBX has no problem at all paying its short term obligations.
TSBX has a Quick ratio of 3.70. This is comparable to the rest of the industry: TSBX outperforms 46.01% of its industry peers.
Industry RankSector Rank
Current Ratio 3.7
Quick Ratio 3.7
TSBX Yearly Current Assets VS Current LiabilitesTSBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.43% over the past year.
TSBX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)41.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.91%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TSBX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.30% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y77.07%
EPS Next 2Y35.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TSBX Yearly Revenue VS EstimatesTSBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 20M 40M 60M 80M 100M
TSBX Yearly EPS VS EstimatesTSBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TSBX. In the last year negative earnings were reported.
Also next year TSBX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TSBX Price Earnings VS Forward Price EarningsTSBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TSBX Per share dataTSBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as TSBX's earnings are expected to grow with 35.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.3%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TSBX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TURNSTONE BIOLOGICS CORP

NASDAQ:TSBX (8/8/2025, 8:09:47 PM)

0.355

+0.01 (+1.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/amc
Earnings (Next)N/A N/A
Inst Owners39.89%
Inst Owner Change0%
Ins Owners3.83%
Ins Owner ChangeN/A
Market Cap8.21M
Revenue(TTM)N/A
Net Income(TTM)-63.01M
Analysts43.33
Price Target1.02 (187.32%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-35.94%
Min EPS beat(2)-92.31%
Max EPS beat(2)20.43%
EPS beat(4)3
Avg EPS beat(4)-13.3%
Min EPS beat(4)-92.31%
Max EPS beat(4)20.43%
EPS beat(8)4
Avg EPS beat(8)-29.72%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-2.05
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-2.47
FCFYN/A
OCF(TTM)-2.47
OCFYN/A
SpS0
BVpS0.86
TBVpS0.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -228.2%
ROE -315.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-84.15%
ROA(5y)N/A
ROE(3y)-108.37%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.7
Quick Ratio 3.7
Altman-Z -18.72
F-Score4
WACC9.85%
ROIC/WACCN/A
Cap/Depr(3y)63.22%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.91%
EPS Next Y77.07%
EPS Next 2Y35.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.71%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.49%
OCF growth 3YN/A
OCF growth 5YN/A

TURNSTONE BIOLOGICS CORP / TSBX FAQ

What is the ChartMill fundamental rating of TURNSTONE BIOLOGICS CORP (TSBX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to TSBX.


What is the valuation status for TSBX stock?

ChartMill assigns a valuation rating of 1 / 10 to TURNSTONE BIOLOGICS CORP (TSBX). This can be considered as Overvalued.


What is the profitability of TSBX stock?

TURNSTONE BIOLOGICS CORP (TSBX) has a profitability rating of 0 / 10.


Can you provide the financial health for TSBX stock?

The financial health rating of TURNSTONE BIOLOGICS CORP (TSBX) is 6 / 10.